Aurinia Pharmaceuticals(US:AUPH)2021-02-26 18:40LUPKYNIS Overview - LUPKYNIS is the first oral therapy approved for active lupus nephritis (LN) in adult patients[6] - LUPKYNIS, combined with standard of care (SoC), showed superior renal response rates compared to SoC alone in clinical trials[16] - Patients treated with LUPKYNIS + SoC were nearly 3 times more likely to have a renal response vs typical SoC alone (OR=2.65)[22] - 75% of patients were on a low steroid dose (< 2.5 mg/day) at 1 year[29] - The expected average annualized net revenue per patient is approximately $65,000[30] Lupus Nephritis (LN) Market - Systemic lupus erythematosus (SLE) affects 200,000 - 300,000 patients in the US[12] - Approximately 1 out of 3 patients with SLE develop LN at the time of SLE diagnosis[12] - Patients with LN face an approximately 45x higher risk of kidney failure compared to non-renal SLE patients[14] Financial Position and Partnerships - The company had $423 million in cash and cash equivalents as of December 31, 2020, to fund operations through 2023[38] - Aurinia has a collaboration and licensing agreement with Otsuka for LUPKYNIS in the EU and Japan, receiving a $50 million upfront payment and potential for up to $50 million in milestone payments, plus tiered royalties ranging from 10% to 20% on net sales[31] - The approved label provides patent protection to December 2037[2]